In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration

Journal of Controlled Release

Volumn 140, Issue 2, 2009, Pages 79-85

  Lee, Eunhye ^a   Kim, Hyungjun ^a   Lee, In Hyun ^a   Jon, Sangyong ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Anticancer therapy; Chitosan; Conjugate; Docetaxel; Oral delivery

Indexed keywords

ANTI-TUMOR EFFICACY; ANTICANCER THERAPY; ANTITUMOR EFFECT; BLOOD CIRCULATION; BODY WEIGHT; CONJUGATE; DOCETAXEL; GLIOBLASTOMAS; HUMAN CANCER CELLS; IN-VITRO; IN-VIVO; LOW MOLECULAR WEIGHT CHITOSANS; MTT ASSAYS; NON-SMALL CELL LUNG CARCINOMATA; NUDE MICE; ORAL ADMINISTRATION; ORAL DELIVERY; PHARMACOKINETIC DATA; PRODRUGS;

CARDIOVASCULAR SYSTEM; CELL CULTURE; CHITOSAN; TOXICITY;

CHITIN;

ANTINEOPLASTIC AGENT; DOCETAXEL; DOCETAXEL LOW MOLECULAR WEIGHT CHITOSAN CONJUGATE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MOUSE; MUCOADHESION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT CHANGE; WEIGHT REDUCTION;

ADHESIVENESS; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; GLIOBLASTOMA; HALF-LIFE; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PRODRUGS; SOLUBILITY; TAXOIDS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350622459     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.08.014     Document Type: Article

References (38)

1. Mangatal L., Adeline M.T., Guénard D., Guéritte-Voegelein F., and Potier P. Application of the vicinal oxymination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron 45 (1989) 4177-4190
2. Walker R.A., Jones J.L., Chappell S., Walsh T., and Shaw J.A. Molecular pathology of breast cancer and its application to clinical management. Cancer Metastasis Rev. 16 (1997) 5-27
3. Kingston D.G., Samranayake G., and Ivey C.A. The chemistry of taxol, a clinically useful anticancer agent. J. Nat. Prod. 53 (1990) 1-12
4. Correia J.J. Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol. Ther. 52 (1991) 127-147
5. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 344 (1994) 1267-1272
6. Ardavanis A., Tryfonopoulos D., Yiotis I., Gerasimidis G., Baziotis N., and Rigatos G. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 15 (2004) 581-585
7. ten Tije A.J., Verweij J., Loos W.J., and Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 42 (2003) 665-685
8. van Zuylen L., Verweij J., and Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 19 (2001) 125-141
9. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., Richie J.P., and Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 6315-6320
10. Kim J.H., Kim Y.S., Kim S., Park J.H., Kim K., Choi K., Chung H., Jeong S.Y., Park R.W., Kim I.S., and Kwon I.C. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Control. Release 111 (2006) 228-234
11. Chan J.M., Zhang L., Yuet K.P., Liao G., Rhee J.W., Langer R., and Farokhzad O.C. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30 (2009) 1627-1634
12. Hwang H.Y., Kim I.S., Kwon I.C., and Kim Y.H. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J. Control. Release 128 (2008) 23-31
13. Nam H.Y., Kwon S.M., Chung H., Lee S.Y., Kwon S.H., Jeon H., Kim Y., Park J.H., Kim J., Her S., Oh Y.K., Kwon I.C., Kim K., and Jeong S.Y. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J. Control. Release 135 (2009) 259-267
14. Einhaus C.M., Retzinger A.C., Perrotta A.O., Dentler M.D., Jakate A.S., Desai P.B., and Retzinger G.S. Fibrinogen-coated droplets of olive oil for delivery of docetaxel to a fibrin(ogen)-rich ascites from of a murine mammary tumor. Clin. Cancer Res. 10 (2004) 7001-7010
15. Gao K., Sun J., Liu K., Liu X., and He Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev. Ind. Pharm. 34 (2008) 1227-1237
16. Lee I.H., Park Y.T., Roh K., Chung H., Kwon I.C., and Jeong S.Y. Stable paclitaxel formulations in oily contrast medium. J. Control. Release 102 (2005) 415-425
17. Hong J.W., Lee I.H., Kwak Y.H., Park Y.T., Sung H.C., Kwon I.C., and Chung H. Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Mol. Cancer Ther. 6 (2007) 3239-3247
18. Immordino M.L., Brusa P., Arpicco S., Stella B., Dosio F., and Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control. Release 91 (2003) 417-429
19. Qiu Y., Gao Y., Hu K., and Li F. Enhancement of skin permeation of docetaxel: a novel approach combining microneedle and elastic liposomes. J. Control. Release 129 (2008) 144-150
20. Fracasso P.M., Rodriguez L.C., Herzog T.J., Fears C.L., Goodner S.A., Govindan R., Picus J., Rader J.S., Tan B.R., and Arquette M.A. Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. Cancer 98 (2003) 610-617
21. Esmaeili F., Dinarvand R., Ghahremani M.H., Amini M., Rouhani H., Sepehri N., Ostad S.N., and Atyabi F. Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies. J. Pharm. Sci. 98 (2009) 2718-2730
22. Liu J., Zahedi P., Zeng F., and Allen C. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J. Pharm. Sci. 97 (2008) 3274-3290
23. Sugahara S., Kajiki M., Kuriyama H., and Kobayashi T.R. Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). J. Control. Release 117 (2007) 40-50
24. Khandare J.J., Jayant S., Singh A., Chandna P., Wang Y., Vorsa N., and Minko T. Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug. Chem. 17 (2006) 1464-1472
25. Banzato A., Bobisse S., Rondina M., Renier D., Bettella F., Esposito G., Quintieri L., Meléndez-Alafort L., Mazzi U., Zanovello P., and Rosato A. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 14 (2008) 3598-3606
26. DeMario M.D., and Ratain M.J. Oral chemotherapy: rationale and future directions. J. Clin. Oncol. 16 (1998) 2557-2567
27. Kruijtzer C.M., Beijnen J.H., and Schellens J.H. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7 (2002) 516-530
28. Lee E., Lee J., Lee I.H., Yu M., Kim H., Chae S.Y., and Jon S. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J. Med. Chem. 51 (2008) 6442-6449
29. Arechabala B., Coiffard C., Rivalland P., Coiffard L.J., and de Roeck-Holtzhauer Y. Comparison of cytotoxicity of various surfactants tested on normal human fibroblast cultures using the neutral red test, MTT assay and LDH release. J. Appl. Toxicol. 19 (1999) 163-165
30. Prabhu R., and Balasubramanian K.A. A novel method of preparation of small intestinal brush border membrane vesicles by polyethylene glycol precipitation. Anal. Biochem. 289 (2001) 157-161
31. Kessler M., Acuto O., Storelli C., Murer H., Müller M., and Semenza G. A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes: their use in investigating some properties of d-glucose and choline transport systems. Biochim. Biophy. Acta. 506 (1978) 136-154
32. Cho S., Park J.H., Yu J., Lee Y., Byun Y., Chung H.C., Kwon I.C., and Jeong S.Y. Preparation and characterization of reconstructed small intestinal brush border membranes for surface plasmon resonance analysis. Pharm. Res. 21 (2004) 55-60
33. Kim K., Cho S., Park J.H., Byun Y., Chung H., Kwon I.C., and Jeong S.Y. Surface plasmon resonance studies of the direct interaction between a drug/intestinal brush border membrane. Pharm. Res. 21 (2004) 1233-1239
34. Sato H., Sato S., Wang Y.M., and Horikoshi I. Add-in macros for rapid and versatile calculation of non-compartmental pharmacokinetic parameters on Microsoft Excel spreadsheets. Comput. Methods Programs Biomed. 50 (1996) 43-52
35. Safavy A., Georg G.I., Vander Velde D., Raisch K.P., Safavy K., Carpenter M., Wang W., Bonner J.A., Khazaeli M.B., and Buchsbaum D.J. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjug. Chem. 15 (2004) 1264-1274
36. Bardelmeijer H.A., Ouwehand M., Buckle T., Huisman M.T., Schellens J.H., Beijnen J.H., and van Tellingen O. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 62 (2002) 6158-6164
37. Feng S.S., Mei L., Anitha P., Gan C.W., and Zhou W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials 30 (2009) 3297-3306
38. Vaishampayan U., Parchment R.E., Jasti B.R., and Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54 (1999) 22-29